Blood Proteins and Imaging Tests May Predict the Risk of Cardiac Sarcoidosis
Risk factors: high BNP levels, myocardial inflammation and reduced left-ventricular function
A study found that an elevated blood level of B-type natriuretic peptide (BNP) is associated with a higher risk of death and serious cardiac complications in people with cardiac sarcoidosis.
The results also suggest that inflammation of the heart muscle (myocarditis) and reduced function of the left ventricle—the chamber that pumps oxygen-rich blood around the body—are associated with a poorer prognosis. These abnormalities can be measured with cardiac imaging.
The researchers described a clinically simple and useful triad of predictors for future events: serum BNP levels, the degree of left-ventricular dysfunction and the intensity of myocardial inflammation.
The study, “Outcome Predictors in a Contemporary Cardiac Sarcoidosis Population: The Role of Brain Natriuretic Peptide, Left-Ventricular Function and Myocardial Inflammation,” was published in the European Journal of Heart Failure.
Cardiac sarcoidosis occurs when granulomas affect the heart
Sarcoidosis is an inflammatory disorder in which clusters of immune cells called granulomas can form in different organs. Cardiac sarcoidosis (CS) means that the heart is involved.
The researchers reviewed data from 319 people with cardiac sarcoidosis treated at Royal Brompton Hospital in the United Kingdom between 2008 and 2018. About two thirds were men and the average age was in the mid-50s. Most (64.9%) had sarcoidosis affecting other parts of the body before CS was diagnosed, with a median disease duration of three years.
“To our knowledge, this study represents the largest single-centre CS cohort offering real-world experience of the condition and its natural history over a three-year period,” the researchers wrote. They noted that, because the study included patients from only one centre, further work in larger populations would be needed to confirm the results.
During follow-up, 26 people died and another 54 experienced serious cardiac events, including life-threatening problems requiring acute care or hospitalisation for heart failure. Statistical analyses were used to identify factors present at diagnosis that predicted these outcomes.
Elevated serum BNP (in the noncellular part of the blood) was associated with more than twice the risk of death or another serious cardiac event, even after other factors were taken into account.
Poor left-ventricular function and myocardial inflammation associated with increased risk
Poor left-ventricular function measured by cardiac MRI and more intense myocardial inflammation were also associated with worse outcomes. The increases in risk were relatively small but statistically significant. Myocardial inflammation was measured using FDG-PET (18F-fluorodeoxyglucose positron-emission tomography).
The researchers noted that, although left-ventricular systolic dysfunction and myocardial inflammation had previously been identified as independent predictors of outcomes in CS, serum BNP levels emerged as a powerful, new risk-stratification tool that remained robust in subgroup analysis.
The subgroup analyses were generally consistent with the overall findings. The researchers noted, however, that patients previously diagnosed with noncardiac sarcoidosis generally had less severe outcomes if they were receiving immunosuppressive medicines. This suggests “that immunosuppressive treatment of CS does indeed favourably affect the natural history of the disease,” the researchers wrote.
These findings may help clinicians identify people who need closer follow-up and earlier treatment. They do not replace an individual assessment by a cardiologist, and larger studies are needed to confirm the results.
Source: https://sarcoidosisnews.com/news/blood-protein-imaging-tests-predict-risk-cardiac/